A retrospective cohort study suggests that adding menopausal hormone therapy (MHT) to semaglutide may lead to greater and more sustained weight loss in menopausal women than semaglutide alone. The findings focus on women using GLP-1 weight-loss treatment alongside FDA-approved hormone therapies used to manage menopause symptoms.
Across outlets, the core takeaway is that the benefit appears stronger with semaglutide than with tirzepatide. Healthline reports results presented at the 2026 Annual Meeting of The Menopause Society, describing greater weight loss for MHT users on semaglutide, while combinations with tirzepatide (such as Zepbound) show only modest early differences and no statistically significant gap at later time points. Both sources frame MHT as intended for symptoms like hot flashes and vaginal dryness rather than weight loss itself.
Outlets also emphasize clinical context and individualized decision-making, noting that treatment choices should be based on symptoms, medical history, and goals rather than adding hormone therapy solely to try to improve GLP-1 weight-loss effects.
